BCTX•benzinga•
BriaCell Therapeutics Announces New Survival Data In Phase 2 Study Of Bria-IMT Plus Check Point Inhibitors; Says 'Median Overall Survival Of 17.3 Months Exceeds Historical Data Of 14.4 Months In TRODELVY, Says 'Survival data in triple negative breast canc
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 16, 2025 by benzinga